Kura Oncology (NASDAQ:KURA) Earns Market Outperform Rating from JMP Securities

Kura Oncology (NASDAQ:KURA)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a note issued to investors on Monday, Benzinga reports. They currently have a $32.00 price objective on the stock. JMP Securities’ target price points to a potential upside of 52.74% from the company’s current price.

KURA has been the subject of several other research reports. Wedbush restated an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Friday. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Kura Oncology in a research report on Friday. Finally, StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, April 15th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.28.

Kura Oncology Stock Up 1.6 %

KURA stock traded up $0.32 during trading on Monday, reaching $20.95. The stock had a trading volume of 194,269 shares, compared to its average volume of 1,273,084. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.60 billion, a P/E ratio of -9.65 and a beta of 0.89. The firm has a fifty day moving average price of $20.66 and a 200 day moving average price of $16.04.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.50) EPS. On average, equities analysts anticipate that Kura Oncology will post -2.35 earnings per share for the current year.

Institutional Trading of Kura Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale increased its stake in Kura Oncology by 216.7% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 95,000 shares of the company’s stock valued at $1,343,000 after buying an additional 65,000 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Kura Oncology by 18.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 563,421 shares of the company’s stock worth $5,138,000 after purchasing an additional 86,141 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Kura Oncology by 10.9% during the 3rd quarter. Bank of New York Mellon Corp now owns 261,744 shares of the company’s stock worth $2,387,000 after purchasing an additional 25,677 shares during the last quarter. Jupiter Asset Management Ltd. increased its stake in shares of Kura Oncology by 234.2% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 57,877 shares of the company’s stock worth $528,000 after purchasing an additional 40,560 shares during the last quarter. Finally, Walleye Capital LLC increased its stake in shares of Kura Oncology by 220.4% during the 3rd quarter. Walleye Capital LLC now owns 264,893 shares of the company’s stock worth $2,416,000 after purchasing an additional 182,221 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.